| Code | Description | Claims | Beneficiaries | Total Paid |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
41,614 |
35,180 |
$3.30M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
38,318 |
34,549 |
$3.21M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
17,879 |
16,691 |
$1.69M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
25,409 |
4,934 |
$1.32M |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
10,232 |
2,310 |
$787K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
6,194 |
5,727 |
$622K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
9,344 |
2,194 |
$550K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
3,744 |
3,158 |
$520K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
10,548 |
8,426 |
$512K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
7,863 |
6,067 |
$471K |
| 80053 |
Comprehensive metabolic panel |
30,489 |
19,371 |
$464K |
| 70450 |
Computed tomography, head or brain; without contrast material |
5,905 |
4,686 |
$446K |
| 96401 |
|
4,909 |
1,591 |
$389K |
| G0378 |
Hospital observation service, per hour |
21,542 |
7,816 |
$354K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
6,954 |
3,106 |
$349K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
70,392 |
43,876 |
$302K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
6,417 |
4,292 |
$295K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
2,282 |
1,858 |
$257K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
1,731 |
1,421 |
$202K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
13,810 |
8,962 |
$188K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
17,657 |
11,021 |
$184K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
7,110 |
6,797 |
$179K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
6,203 |
3,694 |
$178K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
1,923 |
1,502 |
$171K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
3,466 |
2,788 |
$161K |
| 36415 |
Collection of venous blood by venipuncture |
38,639 |
31,453 |
$161K |
| 86850 |
|
5,429 |
3,327 |
$158K |
| 96415 |
|
1,713 |
1,004 |
$151K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
6,835 |
4,914 |
$149K |
| 97113 |
|
1,009 |
290 |
$139K |
| 71046 |
Radiologic examination, chest; 2 views |
7,819 |
6,750 |
$134K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
35,661 |
24,171 |
$126K |
| J2505 |
Injection, pegfilgrastim, 6 mg |
150 |
83 |
$121K |
| 87088 |
|
12,421 |
10,346 |
$120K |
| 76641 |
|
2,151 |
1,797 |
$119K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
5,088 |
4,352 |
$116K |
| 97162 |
|
1,849 |
1,431 |
$116K |
| 82962 |
|
14,901 |
7,164 |
$107K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
5,810 |
1,291 |
$104K |
| 96402 |
|
613 |
445 |
$103K |
| 84702 |
|
16,120 |
13,415 |
$94K |
| 36430 |
|
1,333 |
496 |
$93K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
7,425 |
4,351 |
$92K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
1,231 |
718 |
$90K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
1,028 |
813 |
$86K |
| 86900 |
|
6,439 |
4,124 |
$83K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
3,899 |
3,586 |
$83K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
5,824 |
3,437 |
$76K |
| 97161 |
|
1,523 |
1,142 |
$74K |
| 87486 |
|
3,700 |
3,386 |
$68K |
| 87631 |
|
999 |
969 |
$67K |
| 96367 |
|
2,738 |
1,617 |
$66K |
| 85027 |
|
4,857 |
3,560 |
$62K |
| 96417 |
|
1,595 |
872 |
$61K |
| 84484 |
|
17,461 |
9,959 |
$59K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
2,093 |
1,874 |
$58K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
1,618 |
1,238 |
$56K |
| 71045 |
Radiologic examination, chest; single view |
14,692 |
11,760 |
$54K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,775 |
1,328 |
$54K |
| 76770 |
|
1,046 |
891 |
$51K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
3,067 |
2,645 |
$50K |
| 83735 |
|
4,557 |
2,912 |
$50K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
576 |
189 |
$50K |
| 96377 |
|
68 |
39 |
$49K |
| 81001 |
|
21,291 |
17,686 |
$48K |
| 96411 |
|
337 |
180 |
$48K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,285 |
1,169 |
$48K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
3,871 |
2,611 |
$46K |
| 97010 |
|
880 |
277 |
$45K |
| J1756 |
Injection, iron sucrose, 1 mg |
785 |
360 |
$44K |
| A9576 |
Injection, gadoteridol, (prohance multipack), per ml |
520 |
295 |
$43K |
| 77336 |
|
423 |
150 |
$42K |
| 86901 |
|
6,454 |
4,084 |
$42K |
| 81003 |
|
8,703 |
7,491 |
$41K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
19,296 |
14,696 |
$40K |
| 73610 |
|
975 |
867 |
$39K |
| 83615 |
|
2,731 |
1,720 |
$38K |
| 83880 |
|
1,830 |
1,371 |
$35K |
| 76801 |
|
2,801 |
2,248 |
$34K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
3,271 |
2,667 |
$34K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
4,366 |
2,860 |
$33K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
3,710 |
2,980 |
$33K |
| 84443 |
Thyroid stimulating hormone (TSH) |
5,490 |
4,324 |
$32K |
| 86923 |
|
1,149 |
460 |
$31K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
2,915 |
2,346 |
$31K |
| 85610 |
|
11,456 |
8,494 |
$31K |
| P9040 |
Red blood cells, leukocytes reduced, irradiated, each unit |
149 |
50 |
$31K |
| 93976 |
|
1,520 |
1,337 |
$30K |
| 84100 |
|
2,466 |
1,510 |
$30K |
| J9312 |
Injection, rituximab, 10 mg |
72 |
25 |
$30K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
3,969 |
2,876 |
$28K |
| J2704 |
Injection, propofol, 10 mg |
4,234 |
3,130 |
$28K |
| J1453 |
Injection, fosaprepitant, 1 mg |
593 |
308 |
$27K |
| 81025 |
|
2,536 |
2,287 |
$27K |
| 70496 |
|
79 |
65 |
$26K |
| 76830 |
Ultrasound, transvaginal |
1,258 |
1,103 |
$23K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
596 |
453 |
$23K |
| 93970 |
|
982 |
754 |
$23K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
4,025 |
2,767 |
$22K |
| 82731 |
|
261 |
241 |
$21K |
| 92523 |
|
224 |
198 |
$20K |
| 85730 |
|
6,637 |
5,043 |
$19K |
| 87186 |
|
2,358 |
1,811 |
$19K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
742 |
561 |
$19K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
1,445 |
1,232 |
$19K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
14,757 |
11,556 |
$19K |
| 73130 |
|
582 |
516 |
$19K |
| 73562 |
|
1,415 |
1,155 |
$18K |
| 74021 |
|
820 |
734 |
$18K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
2,046 |
1,326 |
$18K |
| 82607 |
|
1,649 |
1,278 |
$17K |
| 86300 |
|
1,428 |
902 |
$17K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
3,318 |
1,391 |
$16K |
| 73080 |
|
204 |
180 |
$16K |
| C9113 |
Injection, pantoprazole sodium, per vial |
1,456 |
802 |
$16K |
| 73630 |
|
683 |
589 |
$15K |
| 82784 |
|
1,928 |
796 |
$15K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
1,810 |
1,239 |
$15K |
| 87581 |
|
3,694 |
3,385 |
$14K |
| 87040 |
|
5,597 |
2,653 |
$14K |
| 77066 |
Tomosynthesis, mammo |
494 |
402 |
$14K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
692 |
635 |
$13K |
| 84112 |
|
301 |
276 |
$13K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
4,084 |
3,167 |
$13K |
| 80076 |
|
5,850 |
4,774 |
$13K |
| 99215 |
Prolong outpt/office vis |
170 |
158 |
$13K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
8,549 |
4,900 |
$13K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
2,737 |
2,236 |
$13K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
3,645 |
2,913 |
$13K |
| 93971 |
|
1,111 |
895 |
$12K |
| 80061 |
Lipid panel |
4,612 |
3,727 |
$12K |
| 36592 |
|
623 |
203 |
$12K |
| 73110 |
|
380 |
312 |
$12K |
| 82378 |
|
1,771 |
1,274 |
$12K |
| 74019 |
|
1,434 |
1,342 |
$12K |
| 82728 |
|
1,989 |
1,495 |
$12K |
| 73030 |
|
810 |
631 |
$11K |
| 74018 |
|
799 |
674 |
$11K |
| 83690 |
|
8,853 |
7,278 |
$10K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
456 |
406 |
$10K |
| 86334 |
|
822 |
533 |
$10K |
| 83550 |
|
2,000 |
1,515 |
$10K |
| 83540 |
|
2,079 |
1,574 |
$10K |
| 71250 |
|
435 |
323 |
$9K |
| 96523 |
|
599 |
401 |
$9K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
426 |
339 |
$8K |
| P9016 |
Red blood cells, leukocytes reduced, each unit |
109 |
62 |
$8K |
| 82746 |
|
1,290 |
993 |
$7K |
| J8540 |
Dexamethasone, oral, 0.25 mg |
3,696 |
2,938 |
$7K |
| 85379 |
|
3,134 |
2,657 |
$6K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
4,394 |
2,707 |
$6K |
| 77080 |
|
231 |
188 |
$6K |
| 87210 |
|
1,856 |
1,681 |
$6K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
1,430 |
1,227 |
$6K |
| 73140 |
|
141 |
128 |
$6K |
| 86140 |
|
2,753 |
2,454 |
$5K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
49 |
39 |
$5K |
| Q9957 |
Injection, perflutren lipid microspheres, per ml |
503 |
365 |
$5K |
| 88342 |
|
622 |
429 |
$5K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
159 |
135 |
$5K |
| 87507 |
|
348 |
289 |
$5K |
| 87077 |
|
2,751 |
2,032 |
$5K |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
392 |
314 |
$4K |
| 92526 |
|
174 |
63 |
$4K |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
480 |
371 |
$4K |
| 82272 |
|
309 |
204 |
$4K |
| 97535 |
Self-care/home management training, each 15 minutes |
387 |
196 |
$4K |
| 83883 |
|
957 |
602 |
$4K |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
342 |
273 |
$4K |
| 83605 |
|
2,633 |
1,689 |
$4K |
| 72100 |
|
600 |
484 |
$4K |
| 84550 |
|
1,508 |
978 |
$4K |
| 84165 |
|
973 |
637 |
$4K |
| 73590 |
|
73 |
67 |
$3K |
| 70486 |
|
40 |
37 |
$3K |
| 87340 |
|
362 |
268 |
$3K |
| G1010 |
Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program |
5,757 |
3,822 |
$3K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
1,997 |
1,913 |
$3K |
| 84439 |
|
1,610 |
1,280 |
$3K |
| 82550 |
|
1,335 |
1,046 |
$3K |
| C1769 |
Guide wire |
68 |
49 |
$3K |
| 88341 |
|
106 |
61 |
$3K |
| G0257 |
Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility |
74 |
39 |
$2K |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
2,301 |
1,180 |
$2K |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
825 |
492 |
$2K |
| 73090 |
|
145 |
113 |
$2K |
| J0897 |
Injection, denosumab, 1 mg |
95 |
51 |
$2K |
| 70544 |
|
76 |
55 |
$2K |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
248 |
149 |
$2K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
1,316 |
1,053 |
$2K |
| 86403 |
|
194 |
158 |
$2K |
| 84132 |
|
353 |
258 |
$2K |
| 73502 |
|
213 |
169 |
$2K |
| J2060 |
Injection, lorazepam, 2 mg |
1,539 |
983 |
$2K |
| 87070 |
|
631 |
526 |
$2K |
| 77072 |
|
24 |
24 |
$1K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
53 |
36 |
$1K |
| 82248 |
|
835 |
554 |
$1K |
| 94760 |
|
349 |
278 |
$1K |
| 72040 |
|
75 |
55 |
$1K |
| J1940 |
Injection, furosemide, up to 20 mg |
314 |
134 |
$1K |
| G8980 |
Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting |
179 |
167 |
$1K |
| 97166 |
|
21 |
13 |
$1K |
| 77334 |
|
26 |
14 |
$1K |
| 82570 |
|
1,101 |
861 |
$1K |
| 12011 |
|
244 |
219 |
$1K |
| 77065 |
Tomosynthesis, mammo |
52 |
37 |
$1K |
| 77062 |
|
146 |
142 |
$1K |
| 59025 |
Fetal non-stress test |
61 |
52 |
$920.31 |
| 85651 |
|
2,051 |
1,748 |
$917.41 |
| 10060 |
|
83 |
76 |
$915.90 |
| 97116 |
|
132 |
53 |
$860.11 |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
17 |
13 |
$827.93 |
| 92610 |
|
18 |
16 |
$811.11 |
| 12001 |
|
82 |
74 |
$787.64 |
| 84156 |
|
308 |
235 |
$701.73 |
| 84153 |
|
64 |
51 |
$700.40 |
| 82805 |
|
75 |
61 |
$685.95 |
| 29125 |
|
167 |
154 |
$663.22 |
| 96376 |
|
289 |
230 |
$635.81 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
1,773 |
1,014 |
$623.55 |
| 77300 |
|
20 |
12 |
$567.40 |
| 87184 |
|
30 |
12 |
$533.89 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
91 |
81 |
$529.42 |
| 70547 |
|
13 |
12 |
$491.40 |
| 85014 |
|
193 |
102 |
$478.53 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
1,925 |
1,395 |
$453.25 |
| 85384 |
|
613 |
461 |
$443.52 |
| J0456 |
Injection, azithromycin, 500 mg |
216 |
119 |
$427.44 |
| 96368 |
|
49 |
24 |
$421.54 |
| 85045 |
|
539 |
383 |
$393.85 |
| 90715 |
|
286 |
225 |
$370.52 |
| 85018 |
|
192 |
101 |
$346.18 |
| 51701 |
|
1,074 |
987 |
$333.84 |
| 87205 |
|
430 |
350 |
$332.45 |
| 82247 |
|
26 |
16 |
$324.91 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
122 |
66 |
$311.03 |
| 87503 |
|
154 |
65 |
$309.44 |
| 94010 |
|
124 |
96 |
$308.60 |
| J0881 |
Injection, darbepoetin alfa, 1 microgram (non-esrd use) |
24 |
13 |
$289.51 |
| 82043 |
|
270 |
216 |
$287.52 |
| 86704 |
|
23 |
13 |
$267.70 |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
35 |
28 |
$263.09 |
| 77001 |
|
13 |
12 |
$262.47 |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
83 |
66 |
$259.42 |
| 78582 |
|
16 |
13 |
$245.85 |
| 87081 |
|
199 |
189 |
$229.72 |
| 82330 |
|
189 |
138 |
$221.91 |
| 97163 |
|
15 |
12 |
$181.46 |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
778 |
688 |
$174.02 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
32 |
12 |
$114.96 |
| 73620 |
|
28 |
26 |
$106.25 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,275 |
1,159 |
$92.72 |
| 82150 |
|
55 |
50 |
$76.11 |
| A9540 |
Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries |
31 |
26 |
$75.00 |
| 76870 |
|
54 |
53 |
$71.05 |
| 88185 |
|
33 |
13 |
$59.58 |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
998 |
299 |
$50.00 |
| 94618 |
|
17 |
13 |
$33.43 |
| 88184 |
|
17 |
13 |
$29.80 |
| 88304 |
|
170 |
144 |
$16.95 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
46 |
27 |
$11.68 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
44 |
35 |
$5.50 |
| 3725F |
|
7,397 |
4,923 |
$0.00 |
| J1953 |
Injection, levetiracetam, 10 mg |
16 |
13 |
$0.00 |
| 3078F |
|
782 |
578 |
$0.00 |
| 84145 |
|
80 |
63 |
$0.00 |
| 29515 |
|
116 |
110 |
$0.00 |
| 80179 |
|
46 |
40 |
$0.00 |
| J7510 |
Prednisolone oral, per 5 mg |
266 |
248 |
$0.00 |
| 1159F |
|
165 |
160 |
$0.00 |
| 80143 |
|
45 |
39 |
$0.00 |
| 1160F |
|
161 |
156 |
$0.00 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
108 |
71 |
$0.00 |
| 76000 |
|
16 |
12 |
$0.00 |
| J0694 |
Injection, cefoxitin sodium, 1 gm |
51 |
25 |
$0.00 |
| 36600 |
|
45 |
38 |
$0.00 |
| 84295 |
|
14 |
12 |
$0.00 |
| 93356 |
|
26 |
25 |
$0.00 |
| J3370 |
Injection, vancomycin hcl, 500 mg |
117 |
52 |
$0.00 |
| J0744 |
Injection, ciprofloxacin for intravenous infusion, 200 mg |
95 |
46 |
$0.00 |
| U0001 |
Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel |
34 |
14 |
$0.00 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
15 |
15 |
$0.00 |
| 82140 |
|
23 |
13 |
$0.00 |
| J3105 |
Injection, terbutaline sulfate, up to 1 mg |
13 |
12 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
6,423 |
4,252 |
$0.00 |
| 3008F |
|
2,859 |
2,098 |
$0.00 |
| 1126F |
|
1,420 |
1,109 |
$0.00 |
| 1170F |
|
780 |
539 |
$0.00 |
| 3351F |
|
4,313 |
3,110 |
$0.00 |
| 3074F |
|
373 |
295 |
$0.00 |
| 29130 |
|
13 |
12 |
$0.00 |
| 1125F |
|
31 |
26 |
$0.00 |
| 3044F |
|
162 |
124 |
$0.00 |
| 86308 |
|
19 |
18 |
$0.00 |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
18 |
18 |
$0.00 |
| 1111F |
|
21 |
12 |
$0.00 |
| J9070 |
Cyclophosphamide, 100 mg |
47 |
12 |
$0.00 |